断腕求生，国资接盘 5月30日，思创医惠宣布以近3亿元向苍南国资旗下山海数科出售医惠科技，彻底退出智慧医疗赛 道。"医惠科技已严重拖累整体业绩，剥离是为集中资源发展商业智能。"公司在公告中直言。值得关注 的是，苍南国资7月刚通过股权转让成为上市公司实控人，此次接盘被视作"输血式救援"。 登录新浪财经APP 搜索【信披】查看更多考评等级 欺诈发行案再掀波澜 近日，思创医惠（维权）股价暴跌。这场暴跌源于公司最新公告——杭州市公安局已就欺诈发行证券案 向公司调取证据，案件正式进入刑事侦查阶段。这已是该公司继去年1月被浙江证监局重罚8570万元 后，面临的又一次重大危机。 财务造假触目惊心 监管调查揭露了思创医惠的造假链条：2020年，该公司通过全资子公司医惠科技虚构业务，在可转债发 行文件中编造虚假财务数据。其中2020年虚增利润高达8394万元，占当期利润总额的67%。时任董事长 章笠中被重罚750万元并遭10年市场禁入，成为注册制改革后罕见的严惩案例。 造假反噬，核心业务崩盘 造假恶果迅速传导至经营端。作为智慧医疗板块核心，医惠科技因信誉崩塌在公立医院招标中屡屡受 挫，业绩断崖式下跌：2024年营收仅1.69亿 ...

当天，来自全国专精特新企业考察团的52位企业家、20余位企业高管，以及多省市专精特新商协会 代表齐聚广西，共商合作。这些掌握关键核心技术、专注细分领域的创新企业，将深入对接广西产业资 源，共同开拓东盟市场。当前，广西正全力构建"北上广研发＋广西集成＋东盟应用"人工智能发展路 径，期待更多企业携独门技术参与其中，共同开拓AI产业蓝海，加快打造面向东盟的人工智能合作新 高地，让广西成为东盟国家与中国开展人工智能合作的"第一站"。此举受到全国专精特新企业的青 睐。"此次全国专精特新企业广西行活动，就是希望通过'广西渠道'精准对接东盟市场与西部资源，探 索'技术嫁接＋资源互补'模式，在发展企业的同时，构建以广西为出海口的抱团出海机制。"北京专精 特新企业商会一名负责人表示。 会场气氛热烈，合作需求务实多元。企业代表听取广西各设区市推介后，表达了进一步合作意愿。 有环保装备企业计划投资5亿—10亿元建设面向东盟的制造基地；有智慧医疗企业拟布局1500个基层站 点，投入超3亿元；有生态环保企业看好广西沿海港口资源，希望在此打造"液体出海"中转站……当天 下午还举办了绿色低碳经济产业生态、AI＋智能制造产业生态、新一代信息 ...

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is under investigation for suspected fraudulent issuance of securities, with the case currently in the police investigation stage [1] Group 1: Investigation and Legal Issues - The investigation is closely related to previous financial fraud cases, where Sichuang Medical inflated revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflated revenue by 60.96 million yuan and profits by 52.37 million yuan in 2020, accounting for 20.03% and 56.81% of the respective profits [2] - The fraudulent data was included in the annual reports for 2019 and 2020, which were used as important evidence for the issuance of 817 million yuan in convertible bonds in 2021 [3] - The company has faced significant penalties, including a fine of 85.7 million yuan and a 10-year market ban for the former chairman [3] Group 2: Corporate Restructuring - In response to regulatory pressure, the company has made significant adjustments to its ownership structure and business layout, including the resignation of the former chairman and the transfer of control to the Cangnan County Finance Bureau [3] - The company has also divested its subsidiary, Medical Technology Co., which was the main platform for the financial fraud, and has shifted its focus to the Internet of Things sector [4] Group 3: Financial Performance - The company has reported continuous losses, with net profits of -878 million yuan, -874 million yuan, -502 million yuan, and -19.56 million yuan for the years 2022 to 2025 Q1, with a 71.14% reduction in losses for Q1 2025 compared to the same period last year [4] - The company claims that its financial situation has improved since the entry of state-owned capital, with a reduction in losses since 2024 [4] Group 4: Regulatory Environment - The capital market has intensified its crackdown on financial fraud and fraudulent issuance, with a focus on establishing a comprehensive accountability mechanism involving administrative, civil, and criminal responsibilities [5][6] - The ongoing investigation into Sichuang Medical is closely monitored by investors, with the company actively cooperating with the police and preparing compensation plans for affected investors [6]

Core Viewpoint - The resignation of Vice President Hua Songyuan and ongoing investigations into alleged fraudulent securities issuance have negatively impacted the stock price and financial performance of Sichuang Medical Technology Co., Ltd. (思创医惠) [1][4] Group 1: Management Changes - Vice President Hua Songyuan resigned for personal career planning reasons and will no longer hold any position in the company after his resignation [1] - Hua's original term was set from December 6, 2024, to December 5, 2027 [1] Group 2: Financial Performance - Sichuang Medical has reported continuous net losses, with net profits of -878 million yuan in 2022, -874 million yuan in 2023, -502 million yuan in 2024, and -19.56 million yuan in the first quarter of 2025 [3] - The company has faced significant discrepancies in its financial disclosures, leading to regulatory scrutiny and penalties [2][4] Group 3: Legal Issues - The company is under investigation by the Hangzhou Public Security Bureau for alleged fraudulent securities issuance, with evidence being collected [1][4] - In January 2024, the company received administrative penalties from the China Securities Regulatory Commission for fabricating significant false content in public offering documents, resulting in inflated revenues and profits [4][5][6] - The company was fined 81.7 million yuan for the fraudulent activities, and its former chairman was banned from the market for 10 years [6] Group 4: Business Operations - Sichuang Medical operates in two main business segments: business intelligence and smart healthcare, providing IoT solutions for various industries [2] - The company has recently sold its 100% stake in a subsidiary, Medical Technology Co., Ltd., to alleviate financial burdens due to ongoing losses [6]

Core Viewpoint - The company Sichuan Medical Technology Co., Ltd. (思创医惠) is under criminal investigation for financial fraud related to previous fiscal years, following a notification from the Hangzhou Public Security Bureau [1][3][4]. Group 1: Investigation and Legal Actions - The investigation pertains to allegations of fraudulent issuance of securities, with the company required to provide relevant evidence [1][4]. - The investigation is a continuation of prior administrative penalties imposed by the Zhejiang Securities Regulatory Commission, which found the company had inflated revenues and profits through false business activities [5][6]. - The company has stated it will cooperate with the investigation and is currently in discussions regarding potential compensation for affected investors [7]. Group 2: Financial Performance and Adjustments - In 2024, the company reported revenues of approximately 690.77 million yuan, a decrease of 31.33% from the previous year, while the net loss attributable to shareholders was approximately 501.51 million yuan, a reduction in loss of 42.64% compared to 2023 [10][11]. - The company has undergone significant structural changes, including the resignation of its former chairman and a shift in control to new shareholders linked to the Cangnan County Finance Bureau [8][9]. - The company has divested its core business in smart healthcare, selling its subsidiary for 300 million yuan, and is now focusing on the Internet of Things (IoT) sector as part of its strategic pivot [9][10]. Group 3: Regulatory Environment - Recent trends indicate an increase in criminal accountability for financial fraud among listed companies, with regulatory bodies intensifying their oversight and enforcement actions [11].

Core Viewpoint - Sichuang Medical's involvement in financial fraud has led to criminal investigations, with the company cooperating with authorities during the ongoing inquiry [1][3][4]. Group 1: Investigation and Legal Actions - Sichuang Medical received a notice from Hangzhou Public Security Bureau regarding evidence collection for a fraud case related to securities issuance [1]. - The investigation focuses on past financial records and is linked to previous administrative penalties imposed by the Zhejiang Securities Regulatory Commission [3][4]. - The company was previously found to have inflated revenue and profits significantly, with a cumulative revenue inflation of 34.93 million yuan and profit inflation of 33.02 million yuan in 2019, representing 20.03% of total profit for that period [4][5]. Group 2: Financial Performance and Adjustments - In 2024, Sichuang Medical reported revenues of 690.77 million yuan, a decrease of 31.33% from the previous year, while the net loss was 501.51 million yuan, a reduction in losses by 42.64% compared to 2023 [9][10]. - The company has undergone significant restructuring, including the resignation of its former chairman and the sale of its subsidiary, which was the main platform for the fraudulent activities, for 300 million yuan [7][8]. - Following the divestment, the company aims to focus on the Internet of Things (IoT) business, shifting its growth strategy to "focus on IoT, reshape growth engines" [8]. Group 3: Regulatory Environment and Future Outlook - The recent increase in criminal accountability for financial fraud in the industry is highlighted by the Supreme Court and the China Securities Regulatory Commission's joint guidelines aimed at enhancing regulatory scrutiny and penalties for fraudulent activities [10]. - Sichuang Medical is actively engaging with investors regarding potential compensation plans and is committed to fulfilling its legal responsibilities [6].

【导读】思创医惠涉嫌欺诈发行证券案，收到杭州市公安局《调取证据通知书》 中国基金报记者 闻言 8 月 15 日晚间， 思创医惠 公告称，杭州市公安局侦办公司涉嫌欺诈发行证券案，正在调取 公司有关证据材料。 这 是 思 创 医 惠 自 2 0 1 0 年 4 月 3 0 日 上 市 至 今 ， 首 次 在 公 告 中 提 及 杭 州 市 公 安 局 侦 办 其 涉 嫌 欺 诈 发 行 证 券 案 。 截 至 8 月 1 5 日 收 盘 ， 思 创 医 惠 股 价 报 3.9 7 元 / 股 ， 总 市 值 为 4 4.3 8 亿 元 。 截 至 3 月 3 1 日 ， 公 司 股 东 人 数 达 7.3 8 万 户 。 思创医惠涉嫌欺诈发行证券 公告显示， 8 月 14 日，思创医惠收到杭州市公安局出具的《调取证据通知书》。《调取证 据通知书》显示，杭州市公安局侦办公司涉嫌欺诈发行证券案，需要调取公司的有关证据材 料。 思创医惠公告称，目前， 上述案件处于公安机关侦查阶段，尚未有明确结论。 同时，思创医惠涉嫌欺诈发行证券案，尚未披露涉及哪些具体事项，但其于 2024 年 1 月 8 日收到浙江证监局下发的《行政 ...

Core Viewpoint - The launch of the "Weizhi Code, Smart Healthcare. Coding the Future" AI medical coding cloud platform in Weifang marks a significant step in the digital transformation of healthcare in the region, integrating advanced technologies to enhance medical coding accuracy and efficiency [1][3]. Group 1: Event Overview - The AI medical coding cloud platform was introduced at a conference organized by the Weifang Health Commission and Weifang People's Hospital, attended by key figures in the healthcare sector [1]. - The event included a systematic introduction to the "Weizhi Code - AI Coding Cloud Platform," showcasing its development background, achievements, and future plans, along with a demonstration of its functionalities [3]. Group 2: Platform Features and Benefits - The platform utilizes large language model technology for intelligent semantic recognition and medical terminology parsing, enabling automatic extraction of key information from medical records and matching standard codes, thereby improving coding accuracy and efficiency [5]. - It aims to unify coding standards across medical institutions, facilitating real-time data sharing and intelligent verification of coding data, which supports medical quality monitoring and cost control [5]. - The successful establishment of the platform signifies a solid advancement in smart healthcare construction in Weifang, with plans to integrate Western medical coding with traditional Chinese medicine practices [5]. Group 3: Future Plans and Collaboration - The "Weizhi Code" will develop a comprehensive output model consisting of one technical platform, three supporting services, and multiple scenario-based modules, promoting collaboration among government, medical institutions, and enterprises [5]. - The initiative aims to create a growth system characterized by "three-level empowerment, two-level undertaking, and grassroots adaptation," ensuring that smart healthcare benefits a broader population and providing a model for digital transformation in healthcare [5].

Core Viewpoint - The establishment of Peianmei (Zhejiang) Technology Co., Ltd. marks a significant collaboration between a technology company and the local government, aiming to innovate the healthcare service system through advanced technologies like medical models and brain-machine interfaces [1][2]. Group 1: Company Development - Peianmei was founded in September 2024 with a vision to integrate health management into daily life, supported by a diverse group of stakeholders including state-owned enterprises and universities [2][3]. - Within nine months, Peianmei has rapidly advanced in the health technology sector, establishing partnerships with various universities and institutions to develop innovative health solutions [3][4]. Group 2: Strategic Collaborations - Peianmei has formed strategic partnerships with institutions like Northwest A&F University and Yunnan University of Traditional Chinese Medicine to explore areas such as medical nutrition and traditional medicine integration [3][4]. - The company is also collaborating with Shenzen Yintong Health Industry Co., Ltd. and Capital Medical University to innovate in brain-machine interface technologies [4][6]. Group 3: Technological Innovations - Peianmei is developing a comprehensive health ecosystem that spans prevention, diagnosis, treatment, and rehabilitation, including initiatives like the "Health One Card" platform and the "Special Medical Food Research Laboratory" [5][6]. - The company aims to leverage artificial intelligence and big data to enhance healthcare delivery and management, addressing chronic diseases and improving patient outcomes [6][9]. Group 4: Alignment with National Strategy - Peianmei's initiatives align with national strategies such as the "Artificial Intelligence +" action plan, aiming to contribute to the "Healthy China" initiative by transforming health management practices [8][9]. - The company's ultimate goal is to make health management a daily reality for individuals, emphasizing preventive care and data-driven health solutions [9].

Group 1 - Several international investment banks have raised their economic growth forecasts for China, indicating a significant increase in market attractiveness [1] - The influx of global capital into China is driven by the strong performance of domestic technology and advanced manufacturing sectors, exemplified by DeepSeek, showcasing China's potential in technological innovation [1] - The revaluation of Chinese assets is fundamentally linked to a reassessment of future cash flows, profitability, and growth potential, influenced by rapid advancements in AI technology [1] Group 2 - Key sectors to focus on include those benefiting from AI technology and policy support, such as humanoid robots, smart driving, smart healthcare, and AI edge applications [1] - The improvement in industry competition and the release of profits in the Hong Kong technology, internet, and new consumption sectors, which are still reasonably undervalued, are also highlighted as areas of interest [1]